College News

Raid Aljumaily, M.D., hematologist-oncologist at OU Health Stephenson Cancer Center at the University of Oklahoma Health Sciences Center, is serving as an investigator for a National Cancer Institute-sponsored clinical trial for stage II and III non small cell lung cancer patients.

To explore a promising premise in aging research — that changes to the brain’s tiniest blood vessels may play an outsized role in cognitive decline — an OU College of Medicine researcher recently received a $1.7 million grant from the National Institutes of Health.

The 2022 Evening of Excellence gala, which celebrates healthcare and community leaders while raising funds for research at the OU College of Medicine, will be held March 24 at the National Cowboy Hall of Fame and Western Heritage Museum.

Chemo brain is an underrecognized but potentially debilitating side effect of cancer treatment. The phenomenon, formally known as chemotherapy-related cognitive impairment, can arise while patients are undergoing treatment, and it can persist months to years later.